Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors

Details for Australian Patent Application No. 2010300791 (hide)

Owner Allergan, Inc.

Inventors Fang, Wenkui Ken; Wang, Liming; Corpuz, Evelyn G.; Chow, Ken; Im, Wha Bin

Agent Davies Collison Cave

Pub. Number AU-A-2010300791

PCT Pub. Number WO2011/041287

Priority 61/246,642 29.09.09 US

Filing date 28 September 2010

Wipo publication date 7 April 2011

International Classifications

C07D 215/38 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

A61K 31/136 (2006.01) - having the amino group directly attached to the aromatic ring, e.g. benzeneamine

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

19 April 2012 PCT application entered the National Phase

  PCT publication WO2011/041287 Priority application(s): WO2011/041287

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010300795-Internally curing cement based materials

2010300788-Process for preparing biphenyl imidazole compounds